AAAAAA
Results: 1-25/71
Authors:
FATTORE C
CIPOLLA G
GATTI G
BARTOLI A
ORTICELLI G
PICOLLO R
MILLERIOUX L
CIOTTOLI GB
PERUCCA E
Citation: C. Fattore et al., PHARMACOKINETIC INTERACTIONS BETWEEN THEOPHYLLINE AND PRULIFLOXACIN IN HEALTHY-VOLUNTEERS, Clinical drug investigation, 16(5), 1998, pp. 387-392
Authors:
PERUCCA E
Citation: E. Perucca, PHARMACORESISTANCE IN EPILEPSY - HOW SHOULD IT BE DEFINED, CNS drugs, 10(3), 1998, pp. 171-179
Authors:
SPINA E
AVENOSO A
FACCIOLA G
FABRAZZO M
MONTELEONE P
MAJ M
PERUCCA E
CAPUTI AP
Citation: E. Spina et al., EFFECT OF FLUOXETINE ON THE PLASMA-CONCENTRATIONS OF CLOZAPINE AND ITS MAJOR METABOLITES IN PATIENTS WITH SCHIZOPHRENIA, International clinical psychopharmacology, 13(3), 1998, pp. 141-145
Authors:
FACCIOLA G
AVENOSO A
SPINA E
PERUCCA E
Citation: G. Facciola et al., INDUCING EFFECT OF PHENOBARBITAL ON CLOZAPINE METABOLISM IN PATIENTS WITH CHRONIC-SCHIZOPHRENIA, Therapeutic drug monitoring, 20(6), 1998, pp. 628-630
Authors:
DONG SX
PING ZZ
XIAO WZ
SHU CC
BARTOLI A
GATTI G
DURSO S
PERUCCA E
Citation: Sx. Dong et al., EFFECT OF ACTIVE AND PASSIVE CIGARETTE-SMOKING ON CYP1A2-MEDIATED PHENACETIN DISPOSITION IN CHINESE SUBJECTS, Therapeutic drug monitoring, 20(4), 1998, pp. 371-375
Authors:
ZUCCARO P
PACIFICI R
ALTIERI I
AVENOSO A
PELLEGRINI M
SPINA E
PERUCCA E
PICHINI S
Citation: P. Zuccaro et al., ISSUES IN METHODOLOGY AND APPLICATIONS FOR THERAPEUTIC DRUG-MONITORING OF FLUOXETINE AND NORFLUOXETINE ENANTIOMERS, Therapeutic drug monitoring, 20(1), 1998, pp. 20-24
Authors:
BIALER M
LEVY RH
PERUCCA E
Citation: M. Bialer et al., DOES CARBAMAZEPINE HAVE A NARROW THERAPEUTIC PLASMA-CONCENTRATION RANGE, Therapeutic drug monitoring, 20(1), 1998, pp. 56-59
Authors:
PERUCCA E
Citation: E. Perucca, INNOVATIVE MONOTHERAPY TRIAL DESIGNS FOR THE ASSESSMENT OF ANTIEPILEPTIC DRUGS - A CRITICAL-APPRAISAL, European Journal of Clinical Pharmacology, 54(1), 1998, pp. 1-5
Authors:
BAKER GA
CAMFIELD C
CAMFIELD P
CRAMER JA
ELGER CE
JOHNSON AL
DASILVA AM
MEINARDI H
MUNARI C
PERUCCA E
THORBECKE R
Citation: Ga. Baker et al., COMMISSION ON OUTCOME MEASUREMENT IN EPILEPSY, 1994-1997 - FINAL REPORT, Epilepsia, 39(2), 1998, pp. 213-231
Authors:
PERUCCA E
GRAM L
AVANZINI G
DULAC O
Citation: E. Perucca et al., ANTIEPILEPTIC DRUGS AS A CAUSE OF WORSENING SEIZURES, Epilepsia, 39(1), 1998, pp. 5-17
Authors:
GUERRINI R
BELMONTE A
CANAPICCHI R
CASALINI C
PERUCCA E
Citation: R. Guerrini et al., REVERSIBLE PSEUDOATROPHY OF THE BRAIN AND MENTAL DETERIORATION ASSOCIATED WITH VALPROATE TREATMENT, Epilepsia, 39(1), 1998, pp. 27-32
Authors:
DERIL GM
MORATTI R
PERUCCA E
Citation: Gm. Deril et al., TOTAL AND NON-PROTEIN-BOUND FRACTIONS OF 3,4-DIHYDROXYPHENYLALANINE, Clinical chemistry, 44(4), 1998, pp. 895-895
Authors:
PERUCCA E
Citation: E. Perucca, A PHARMACOLOGICAL AND CLINICAL REVIEW ON TOPIRAMATE, A NEW ANTIEPILEPTIC DRUG, Pharmacological research, 35(4), 1997, pp. 241-256
Authors:
AVENOSO A
SPINA E
CAMPO G
FACCIOLA G
FERLITO M
ZUCCARO P
PERUCCA E
CAPUTI AP
Citation: A. Avenoso et al., INTERACTION BETWEEN FLUOXETINE AND HALOPERIDOL - PHARMACOKINETIC AND CLINICAL IMPLICATIONS, Pharmacological research, 35(4), 1997, pp. 335-339
Authors:
PERUCCA E
Citation: E. Perucca, EVALUATION OF DRUG-TREATMENT OUTCOME IN EPILEPSY - A CLINICAL PERSPECTIVE, Pharmacy world & science, 19(5), 1997, pp. 217-222
Authors:
BIALER M
JOHANNESSEN SI
KUPFERBERG HJ
LEVY RH
LOISEAU P
PERUCCA E
Citation: M. Bialer et al., CONFERENCE REPORT - PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT-CONFERENCE (VOL 25, PG 299, 1996), Epilepsy research, 26(3), 1997, pp. 465-465
Authors:
PERUCCA E
MARCHIONI E
SORAGNA D
SAVOLDI F
Citation: E. Perucca et al., FLUOXETINE-INDUCED MOVEMENT-DISORDERS AND DEFICIENT CYP2D6 ENZYME-ACTIVITY, Movement disorders, 12(4), 1997, pp. 624-624
Authors:
SPINA E
AVENOSO A
CAMPO GM
SCORDO MG
CAPUTI AP
PERUCCA E
Citation: E. Spina et al., EFFECT OF KETOCONAZOLE ON THE PHARMACOKINETICS OF IMIPRAMINE AND DESIPRAMINE IN HEALTHY-SUBJECTS, British journal of clinical pharmacology, 43(3), 1997, pp. 315-318
Authors:
SPINA E
ARENA D
SCORDO MG
FAZIO A
PISANI F
PERUCCA E
Citation: E. Spina et al., ELEVATION OF PLASMA CARBAMAZEPINE CONCENTRATIONS BY KETOCONAZOLE IN PATIENTS WITH EPILEPSY, Therapeutic drug monitoring, 19(5), 1997, pp. 535-538
Authors:
BARTOLI A
GUERRINI R
BELMONTE A
ALESSANDRI MG
GATTI G
PERUCCA E
Citation: A. Bartoli et al., THE INFLUENCE OF DOSAGE, AGE, AND COMEDICATION ON STEADY-STATE PLASMALAMOTRIGINE CONCENTRATIONS IN EPILEPTIC CHILDREN - A PROSPECTIVE-STUDY WITH PRELIMINARY ASSESSMENT OF CORRELATIONS WITH CLINICAL-RESPONSE, Therapeutic drug monitoring, 19(3), 1997, pp. 252-260
Authors:
SPINA E
GITTO C
AVENOSO A
CAMPO GM
CAPUTI AP
PERUCCA E
Citation: E. Spina et al., RELATIONSHIP BETWEEN PLASMA DESIPRAMINE LEVELS, CYP2D6 PHENOTYPE AND CLINICAL-RESPONSE TO DESIPRAMINE - A PROSPECTIVE-STUDY, European Journal of Clinical Pharmacology, 51(5), 1997, pp. 395-398
Authors:
BARTOLI A
GATTI G
CIPOLLA G
BARZAGHI N
VELIZ G
FATTORE C
MUMFORD J
PERUCCA E
Citation: A. Bartoli et al., A DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ON THE EFFECT OF VIGABATRIN ON IN-VIVO PARAMETERS OF HEPATIC-MICROSOMAL ENZYME-INDUCTION AND ON THE KINETICS OF STEROID ORAL-CONTRACEPTIVES IN HEALTHY FEMALE VOLUNTEERS, Epilepsia, 38(6), 1997, pp. 702-707
Authors:
BAREL S
YAGEN B
SCHURIG V
SOBACK S
PISANI F
PERUCCA E
BIALER M
Citation: S. Barel et al., STEREOSELECTIVE PHARMACOKINETIC ANALYSIS OF VALNOCTAMIDE IN HEALTHY-SUBJECTS AND IN PATIENTS WITH EPILEPSY, Clinical pharmacology and therapeutics, 61(4), 1997, pp. 442-449
Authors:
PERUCCA E
Citation: E. Perucca, ESTABLISHED ANTIEPILEPTIC DRUGS, Bailliere's clinical neurology, 5(4), 1996, pp. 693-722
Authors:
BIALER M
JOHANNESSEN SI
KUPFERBERG HJ
LEVY RH
LOISEAU P
PERUCCA E
Citation: M. Bialer et al., PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE, Epilepsy research, 25(3), 1996, pp. 299-319